| Drug General Information |
| Drug ID |
D0M3OR
|
| Former ID |
DNCL002531
|
| Drug Name |
KW-2450
|
| Indication |
Breast cancer [ICD9: 174, 175; ICD10:C50]
|
Discontinued in Phase 1/2 |
[1]
|
|---|
| Company |
Kyowa Hakko Kirin Pharma
|
| Structure |
|
Download
2D MOL
|
| Target and Pathway |
| Target(s) |
Insulin-like growth factor I receptor |
Target Info |
Modulator |
[2]
|
|---|
| Insulin receptor |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Oocyte meiosis
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Long-term depression
|
|
Ovarian steroidogenesis
|
|
Progesterone-mediated oocyte maturation
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanomahsa04014:Ras signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Insulin signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorption
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascadeP00032:Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
PI3 kinase pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
SHP2 signaling
|
|
IGF1 pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Integrins in angiogenesis
|
|
Stabilization and expansion of the E-cadherin adherens junctioninsulin_pathway:Insulin Pathway
|
|
Signaling events mediated by PTP1B
|
|
Signaling events mediated by TCPTP
|
|
Insulin-mediated glucose transport
|
|
PathWhiz Pathway
|
Insulin Signalling
|
|
Leucine Stimulation on Insulin Signaling
|
|
Reactome
|
IRS-related events triggered by IGF1R
|
|
SHC-related events triggered by IGF1RR-HSA-74713:IRS activation
|
|
Signal attenuation
|
|
Insulin receptor signalling cascade
|
|
Insulin receptor recycling
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
Insulin Signaling
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Apoptosis
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
MicroRNAs in cardiomyocyte hypertrophyWP710:DNA Damage Response (only ATM dependent)
|
|
Nanoparticle triggered autophagic cell death
|
|
AGE/RAGE pathway
|
|
Signaling by Insulin receptor
|
|
Folate Metabolism
|
|
Type II diabetes mellitus
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
AMPK Signaling
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030562) |
|---|
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. |
|---|
